ledfoki.blogg.se

TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. The new name, logo and branding elements were introduced to better reflect Theriva's position. TOVX), ("Theriva" or the "Company") is the new name of Synthetic Biologics, Inc. Synthetic Biologics Rebrands as Theriva Biologics | Morningstar The new name, logo and branding elements were introduced to better reflect. Or the “Company&CloseCurlyDoubleQuote ) is the new name of Synthetic Biologics, Inc. The average price target represents a 24.12 change from the last price of 9.37.

The average price target is 11.63 with a high forecast of 15.00 and a low forecast of 9.00. The new name, logo and branding elements were introduced to better reflect Theriva's position as a clinical-stage. (24.12 Upside) Based on 3 Wall Street analysts offering 12 month price targets for Ardmore Shipping in the last 3 months. ("Theriva" or the "Company") is the new name of Synthetic Biologics, Inc. The new name, logo and branding elements were introduced to better reflect Theriva. Synthetic Biologics Rebrands as Theriva Biologics physical and immunosuppressive barrier to cancer treatment SYN-004 (ribaxamase) which is designed to degrade certain commonly. On its last earning announcement, the company reported a loss of -0.59$ per share. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.Īt the moment the company doesn't generate any revenue. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The new name, logo and branding elements were introduced to better reflect Theriva’s position as. The new name, logo and branding elements were introduced to better reflect Theriva's position as a clinical-stage.